Novo Nordisk Annual Report 2021 slide image

Novo Nordisk Annual Report 2021

Financial statements of the parent company 8 Financial assets Invest- ments in Amounts owed by subsi- affiliated Invest- ment in associated Other securities and invest- DKK million diaries companies company ments 2021 2020 Cost at the beginning of the year 29,174 4,047 105 1,220 34,546 18,493 Investments during the year 19,698 1,255 67 21,020 29,629 Divestments and repayments during the year (989) (590) (1,579) (13,576) Cost at the end of the year 48,872 4,313 105 697 53,987 34,546 Value adjustments at the beginning of the year 26,255 (245) 111 (452) 25,669 28,803 Profit/(loss) before tax 19,635 19,635 18,187 Share of result after tax in associated company (13) (13) 21 Income taxes on profit for the year (2,006) (2,006) (3,748) Market value adjustment Dividends received 75 75 (171) (11,050) (4) (11,054) (16,785) Divestments during the year 216 216 (3) Effect of exchange rate adjustment charged to the income statement 281 17 298 Effect of exchange rate adjustment charged to equity 2,603 10 2,613 (3,103) Other adjustments 500 500 2,468 Value adjustments at the end of the year 35,937 46 46 94 (144) 35,933 Unrealised internal profit at the beginning of the year (16,617) Unrealised internal profit movements in the year (750) (16,617) (750) 25,669 (13,420) (4,045) Effect of exchange rate adjustment charged to equity (989) (989) 848 Unrealised internal profit at the end of the year Carrying amount at the end of the year (18,356) 66,453 4,359 199 553 (18,356) 71,564 (16,617) 43,598 Novo Nordisk Annual Report 2021 102 The carrying amount of investments in subsidiaries does not include capitalised goodwill at the end of the year. For a list of companies in the Novo Nordisk Group, please refer to note 5.7 to the consolidated financial statements.
View entire presentation